Literature DB >> 19762067

Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features.

Kurt B Hodges1, Antonio Lopez-Beltran, Darrell D Davidson, Rodolfo Montironi, Liang Cheng.   

Abstract

The 2004 World Health Organization classification system for urothelial neoplasia classifies flat-related preneoplastic lesions as urothelial hyperplasia (flat and papillary), reactive urothelial atypia, urothelial atypia of unknown significance, urothelial dysplasia (low-grade intraurothelial neoplasia), and urothelial carcinoma in situ (high-grade intraurothelial neoplasia). Each lesion is defined with precise nomenclature and strict morphologic criteria. In many cases, morphologic features alone suffice for diagnosis. Other cases may require a panel of immunohistochemical antibodies consisting of cytokeratin 20, p53, and CD44 for diagnosis. Recent molecular studies have provided further insight into the premalignant potential of these urothelial lesions. Herein, we present a review of flat urothelial lesions of the urinary bladder as defined by the 2004 World Health Organization classification with focus on the clinicopathologic, immunohistochemical, and molecular features. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762067     DOI: 10.1016/j.humpath.2009.07.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.

Authors:  Haiping Zhou; Hong-ying Huang; Ellen Shapiro; Herbert Lepor; William C Huang; Moosa Mohammadi; Ian Mohr; Moon-shong Tang; Chuanshu Huang; Xue-ru Wu
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

2.  Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis.

Authors:  Rui M Gil da Costa; Paula A Oliveira; Carmen Vasconcelos-Nóbrega; Regina Arantes-Rodrigues; Rosário Pinto-Leite; Aura A Colaço; Luis F de la Cruz; Carlos Lopes
Journal:  Int J Exp Pathol       Date:  2015-10-30       Impact factor: 1.925

Review 3.  Contemporary management of low-risk bladder cancer.

Authors:  Johannes Falke; J Alfred Witjes
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

4.  Dysplastic urothelial changes accompany empagliflozin administration in urinary bladder of experimental diabetes.

Authors:  Ahmed A M Abdel-Hamid; Alaa El-Din L Firgany
Journal:  Int J Exp Pathol       Date:  2020-02-10       Impact factor: 1.925

5.  How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?

Authors:  Rodolfo Montironi; Liang Cheng; Marina Scarpelli; Roberta Mazzucchelli; Antonio Lopez-Beltran
Journal:  Diagn Pathol       Date:  2011-04-07       Impact factor: 2.644

6.  Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection.

Authors:  Selda Aydin; Anne-France Dekairelle; Jérôme Ambroise; Jean-François Durant; Michel Heusterspreute; Yves Guiot; Jean-Pierre Cosyns; Jean-Luc Gala
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

7.  Evaluation of P53 and CK20 Immunohistochemical Markers in Comparison with Morphologic Findings in Low- and High-grade Urothelial Carcinomas.

Authors:  Mahsa Ahadi; Afshin Moradi; Banafshe Bayat; Hanieh Zham; Seyed Jalil Hosseini; Sara Zahedifar; Afsoon Taghavi
Journal:  Iran J Pathol       Date:  2021-05-09

8.  Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection.

Authors:  Julie Steinestel; Marcus V Cronauer; Johannes Müller; Andreas Al Ghazal; Peter Skowronek; Annette Arndt; Klaus Kraft; Mark Schrader; Andres J Schrader; Konrad Steinestel
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

9.  Reinventing diagnostics for personalized therapy in oncology.

Authors:  Diponkar Banerjee
Journal:  Cancers (Basel)       Date:  2010-06-02       Impact factor: 6.639

10.  Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67.

Authors:  Mojgan Asgari; Mahtab Nabi Maybodi; Maryam Abolhasani
Journal:  Med J Islam Repub Iran       Date:  2016-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.